

Date: 15th May, 2017

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Tower, Dalal Street,
Fort, Mumbai – 400 001

Dear Sir/Madam,


Sub: Alembic Pharmaceuticals Limited receives USFDA Approval for Fenofibric Acid Delayed-Release Capsules

With reference to the captioned subject, this is to inform the exchange that the Company has received U.S. Food & Drug Administration (FDA) approval for Fenofibric Acid Delayed-Release Capsules. Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director – Finance & CFO

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123

PRESS RELEASE

15th May, 2017, Vadodara, India

Alembic Pharmaceuticals receives USFDA Approval for Fenofibric Acid Delayed-Release Capsules

Alembic Pharmaceuticals Limited today announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Trilipix® Delayed-Release Capsules, 45 mg and 135 mg, of Abbvie Inc. Fenofibric Acid Delayed-Release Capsules are indicated as an adjunctive therapy to diet to reduce triglycerides (TG) in patients with severe hypertriglyceridemia and to reduce elevated LDL-C, total cholesterol (Total-C), TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia.

Fenofibric Acid Delayed-Release Capsules have an estimated market size of US\$ 93 million for twelve months ending December 2016 according to IMS.

Alembic now has a total of 56 ANDA approvals (50 final approvals and 6 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at <http://www.alembicpharmaceuticals.com>;
(Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APL LTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 - 306 11681	Phone: +91 265 - 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123